Danuglipron

Cat. No.:	HY-125824
CAS No.:	2230198-02-2
Molecular Formula:	$C_{31}H_{30}FN_5O_4$
Molecular Weight:	555.6
Target:	GCGR
Pathway:	GPCR/G Protein

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (224.98 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7999 mL	8.9993 mL	17.9986 mL
5 mM	0.3600 mL	1.7999 mL	3.5997 mL
10 mM	0.1800 mL	0.8999 mL	1.7999 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (3.74 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (3.74 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (3.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R)[1][2].

IC_{50} & Target

GLP-1R[1][2]

In Vivo

PF-06882961 (3-240 mg per day) shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat[3]. PF-06882961 (3-240 mg per day) results one death in an earlier 2-week monkey study at the highest PF-06882961 dose given

in that study. No deaths are seen in the 6-week monkey study or any other monkey studies at any of the doses given[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-week rat[3]
Dosage:	3 mg, 10 mg, 30 mg, 60 mg, 120 mg, and 240 mg per day
Administration:	
Result:	Mild to moderate damage to the heart, moderate to severe effects on the thymus gland, and mild to moderate stomach ulcers at the highest dose level.

Animal Model:	2-week and 6-week monkeys[3]
Dosage:	3 mg, 10 mg, 30 mg, 60 mg, 120 mg, and 240 mg per day
Administration:	
Result:	No side effects were observed in the 6-week monkey study. There was one death in an earlier 2-week monkey study at the highest dose. No deaths were seen in the 6-week monkey study or any other monkey studies at any of the doses given.

CUSTOMER VALIDATION

- Expert Opin Emerg Drugs. 2021 Jun 28.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. 20th SCI/RSC Medicinal Chemistry Symposium.

[2]. Méndez M, et al. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). J Med Chem. 2019 Oct 23.

[3]. POSSIBLE SIDE EFFECTS AND RISKS OF THE STUDY DRUG AND PROCEDURES.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA